RxDoctor Payments Data

Victoria Leonichev, DO

Cardiovascular Disease · White Plains, NYNPI 1467783936

Payments from drug & device makers

$1,700in general payments, 2019–2025

Across 79 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$528
  • Johnson & Johnson$335
  • Pfizer$277
  • Amgen$181
  • Astellas Pharma US Inc$134
  • Sanofi-aventis U.S. LLC$72
  • plus $172 from 5 others

What the payments were for

  • Food & beverage$1,61095%
  • Education$905%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,700 in reported general payments places this provider in the 50th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$109,225
Medicare patients
1,013
Services billed
1,991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban42$47,031
EntrestoSacubitril/Valsartan22$17,557
Repatha SureclickEvolocumab21$12,062
JardianceEmpagliflozin14$11,249
Metoprolol Succinate215$1,977
Atorvastatin Calcium177$1,616
Amlodipine Besylate146$992
Diltiazem 24hr Er (Cd)Diltiazem Hcl19$782
Ezetimibe12$553
Losartan Potassium69$547
Chlorthalidone23$528
Rosuvastatin Calcium26$422
ClopidogrelClopidogrel Bisulfate36$417
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide22$300
Metoprolol Tartrate55$169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$277$47,03142 claims
NovartisEntresto$528$17,55722 claims
Boehringer IngelheimJardiance$46$11,24914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in White Plains

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →